- Clinical and serological prognostic markers in primary biliary cholangitis
-
Wilhelmi M
- KMID: 2514776
- Clin Mol Hepatol.
- 2021 Apr;27(2):360-361.
- doi: 10.3350/cmh.2021.0088
-
- CITED
-
- Close
- SHARE
-
- Close
- Another oral antiviral treatment, but still far away from hepatitis B virus cure
-
Tseng TC
- KMID: 2514769
- Clin Mol Hepatol.
- 2021 Apr;27(2):281-282.
- doi: 10.3350/cmh.2021.0072
-
- CITED
-
- Close
- SHARE
-
- Close
- Biopsy or cytology for diagnosing hepatic focal lesions?
-
Kim H
- KMID: 2514768
- Clin Mol Hepatol.
- 2021 Apr;27(2):278-280.
- doi: 10.3350/cmh.2021.0031
-
- CITED
-
- Close
- SHARE
-
- Close
- A need for patient-centered care in managing patients with liver cirrhosis
-
Yoon EL
- KMID: 2514766
- Clin Mol Hepatol.
- 2021 Apr;27(2):270-272.
- doi: 10.3350/cmh.2021.0001
-
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
-
Wijarnpreecha K, Aby ES, Ahmed A, Kim D
- KMID: 2514762
- Clin Mol Hepatol.
- 2021 Apr;27(2):221-235.
- doi: 10.3350/cmh.2020.0239
Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of... -
- CITED
-
- Close
- SHARE
-
- Close
- Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
-
Yip TCF, Wong GLH, Wong VWS
- KMID: 2514767
- Clin Mol Hepatol.
- 2021 Apr;27(2):273-277.
- doi: 10.3350/cmh.2021.0019
-
- CITED
-
- Close
- SHARE
-
- Close
- Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
-
Torimura T, Iwamoto H
- KMID: 2514763
- Clin Mol Hepatol.
- 2021 Apr;27(2):236-245.
- doi: 10.3350/cmh.2020.0204
Hepatocellular carcinoma (HCC) is usually accompanied by chronic liver damage, which sometimes influences the selection of HCC treatment. The Barcelona Clinic Liver Cancer (BCLC) staging system, which was first introduced... -
- CITED
-
- Close
- SHARE
-
- Close
- Direct comparison of biopsy techniques for hepatic malignancies
-
Huang SC, Liang JD, Hsu SJ, Hong TC, Yang HC, Kao JH
- KMID: 2514772
- Clin Mol Hepatol.
- 2021 Apr;27(2):305-312.
- doi: 10.3350/cmh.2020.0301
Background/Aims: The core needle biopsy (CNB), fine needle aspiration cytology (FNAC) and touch imprint cytology (TIC) are commonly used tools for the diagnosis of hepatic malignancies. However, little is known... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis
-
Xu G, Wang YM, Ying MM, Chen SD, Li ZR, Ma HL, Zheng MH, Wu J, Ding C
- KMID: 2514774
- Clin Mol Hepatol.
- 2021 Apr;27(2):329-345.
- doi: 10.3350/cmh.2020.0261
Background/Aims: Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) characterized by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis. We aimed to investigate the usefulness of... -
- CITED
-
- Close
- SHARE
-
- Close
- Current and future strategies for the treatment of chronic hepatitis C
-
Alshuwaykh O, Kwo PY
- KMID: 2514764
- Clin Mol Hepatol.
- 2021 Apr;27(2):246-256.
- doi: 10.3350/cmh.2020.0230
Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma worldwide. While hepatitis C has been treated for decades with some success, the introduction of direct... -
- CITED
-
- Close
- SHARE
-
- Close
- From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
-
Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW, On behalf of Korean NAFLD Study Group
- KMID: 2514765
- Clin Mol Hepatol.
- 2021 Apr;27(2):257-269.
- doi: 10.3350/cmh.2021.0067
There is some dissatisfaction with the term “nonalcoholic fatty liver disease (NAFLD),” which overemphasizes alcohol and underemphasizes the importance of metabolic risk factors in this disease. Recently, a consensus recommended... -
- CITED
-
- Close
- SHARE
-
- Close
- Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study
-
Jang SY, Rou WS, Kim SH, Lee BS, Eun HS
- KMID: 2514770
- Clin Mol Hepatol.
- 2021 Apr;27(2):283-294.
- doi: 10.3350/cmh.2020.0227
Background/Aims: Current evidence suggests that liver cirrhosis (LC) causes severe psychological stress and depression, which are risk factors for suicide. Although previous studies reported the association between LC and suicidal... -
- CITED
-
- Close
- SHARE
-
- Close
- Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
-
Jeon MY, Kim BK, Lee JS, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, Kim SU
- KMID: 2514771
- Clin Mol Hepatol.
- 2021 Apr;27(2):295-304.
- doi: 10.3350/cmh.2020.0216
Background/Aims: The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during... -
- CITED
-
- Close
- SHARE
-
- Close
- Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognos- tic factor in hepatitis C virus-related hepatocellular carcinoma
-
Lin CC, Liu TW, Yeh ML, Tsai YS, Tsai PC, Huang CF, Huang JF, Chuang WL, Dai CY, Yu ML
- KMID: 2514773
- Clin Mol Hepatol.
- 2021 Apr;27(2):313-328.
- doi: 10.3350/cmh.2020.0247
Background/Aims: Growth hormone (GH) is the main regulator of somatic growth, metabolism, and gender dimorphism in the liver. GH receptor (GHR) signaling in cancer is derived from a large body... -
- CITED
-
- Close
- SHARE
-
- Close
- Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
-
Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Yang JM, Kim KH, Han KH, Um SH
- KMID: 2514775
- Clin Mol Hepatol.
- 2021 Apr;27(2):346-359.
- doi: 10.3350/cmh.2020.0307
Background/Aims: Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir... -
- CITED
-
- Close
- SHARE
-
- Close
